TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has been recently diagnosed and is presently untreated for Open-Angle Glaucoma Or Ocular Hypertension With An iop of at least 27 mmhg in at least one eye (patient's worse eye)~* Patient Already Diagnosed With Open-Angle Glaucoma Or Ocular Hypertension And Untreated For At Least 30 Days Are Eligible For The Study If They Have An Iop Of 27 Mmhg Or More In At Least One Eye~Exclusion Criteria:~* A History Of Any Illness That, In The Opinion Of The Investigator, Might Confound The Results Of The Study Or Pose Additional Risk By Administering Dorzolamide-Timolol (Cosopt®) Or Prostaglandins~* The Presence Of Any Fundus Pathology Likely To Change During The Study Or To Influence Iop (Background Of Diabetic Retinopathy Is Permitted)~* Any Contraindication To The Use Of Cosopt® Including: - Bronchospasm, Including Bronchial Asthma Or A History Of Bronchial Asthma Or Chronic Obstructive Pulmonary Disease. - Sinus Bradycardia, Second Or Third Degree Av Block, Cardiac Failure (Grade Iii And Iv), Cardiogenic Shock~* Patient On Oral Carbonic Anhydrase Inhibitor, Concomitant Systemic Or Dermatological Medication Known To Affect The Iop, E.G. Clonidine, Corticosteroids, Oral Beta-Blocking Agents~* Pregnant Woman Or A Woman Of Childbearing Potential Who Is Sexually Active And Not Using An Acceptable Method Of Contraception (For Ex: Oral Contraceptive, Diaphragm, Contraceptive Sponge, Intra-Uterine Device, Long-Acting Contraceptive Injections, Double-Barrier Methods) Beginning At Least 7 Days Prior To Treatment And Continuing At Least 14 Days After The Last Visit Or The Discontinuation Visit. (Women Who Are Postmenopausal Or Have Received A Hysterectomy Or Have Undergone Tubal Ligature Are Considered As Not Having Childbearing Potential.)~* Severe Renal Impairment (Serum Creatinine \> 150 umol/L Or Creatinine Clearance \< 30 ml/min)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dorzolamide HCl/timolol maleate
- 2 (Type: EXPERIMENTAL): dorzolamide hydrochloride/timolol maleate + prostaglandin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Stable fiber therapy~* Normal colonoscopy/sigmoidoscopy~* Able to refrain from use of medications known to treat or associated with constipation symptoms~* Experiences abdominal discomfort/pain associated with bowel movements~* Reports decreased bowel movement frequency and/or other symptoms associated with constipation~Exclusion Criteria:~* Diarrhea-predominant or alternating (diarrhea and constipation cycling) irritable bowel syndrome (IBS), or constipation other than that associated with IBS~* Open gastrointestinal or abdominal surgery prior to IBS onset~* Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, unexplained weight loss or rectal bleeding~* Uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, other systemic disease, or abnormal laboratory tests per investigator discretion~* If female, is currently pregnant or nursing, or plans to become pregnant or nurse during the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lubiprostone (Type: EXPERIMENTAL): 8 mcg capsule twice daily (BID)
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsule twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be low risk, as defined by either A or B below:~   A. The modified Hestia criteria:~  * Systolic blood pressure \> 100 mm Hg~  * No thrombolysis needed~  * No active bleeding~  * SaO2 \>94% while breathing room air~  * Not already anticoagulated~  * No more than two doses of IV narcotics in the emergency department~  * Other medical or social reasons to admit~  * Creatinine clearance \>30mL/min~  * Not pregnant, severe liver disease or heparin induced thrombocytopenia OR~   B. The physician opinion that a patients' overall social and medical situation is favorable for home treatment and the patient has a zero score on the simplified pulmonary embolism severity index (sPESI).~   All of the following must true:~  * Age \< 81 years~  * No history of cancer~  * No history of heart failure or chronic lung disease~  * Pulse \< 110 beats/min~  * SBP \> 99 mm Hg~  * O2 sat \>89%%~   We have chosen either criteria because both have been found equal in terms of safety for outpatient treatment of PE.6,22 Hestia includes implicit questions that most emergency physicians would use as criteria for discharge (e.g., overall medical status and social situation), whereas sPESI does not. For that reason, we have added the additional gestalt assessment question about physician discretion.~2. Patients must be discharged in \<24 hours after triage in an ED visit with diagnosis of VTE using objective criteria in the emergency department.~Exclusion Criteria:~* VTE diagnosis while taking anticoagulants with evidence of compliance (e.g., physician opinion that patient is taking a Eliquis®, Xarelto® or Pradaxa®, low molecular weight heparin injections or warfarin as prescribed for any condition)~* Sensitivity or contraindication to use of apixaban~* Troponin assay value, drawn as part of usual care and found to be positive, using local standards~* High risk for hemorrhage defined by a score\>1.5 using the method of Ruiz Gimenez.3 (Note that several criteria are already excluded by Hestia):~Recent major bleeding, 2 points Creatinine levels \>1.2 mg/dl, 1.5 points Anemia, 1.5 points Cancer, 1 point Clinically overt PE, 1 point Age \>75 years, 1 point

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban for VTE (Type: None): None
- Rivaroxaban for VTE (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with mild to moderate COPD (GOLD stage I, II and III)-~* 10 pack-year smoking history or greater and ceased to smoke at least for 2 months prior to recruitment~* Subjects taking H2 antagonists, Imodium or loratadine and willing to stop during the study period~Exclusion criteria:~* COPD subjects with \>80% or \<35% predicted~* Current smokers~* Known allergy/sensitivity to quercetin~* Subjects with primary diagnosis of asthma~* Upper respiratory tract infection within two weeks of the screening visit~* Acute bacterial infection requiring antibiotics within two weeks of screening~* Emergency treatment or hospitalization within one month of screening~* Pregnant or lactating mothers~* Women who don't consent to take pregnancy test~* Unwillingness to stop flavonoid supplementation~* Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener~* Daily oral steroid treatment, warfarin, cyclosporine (neural, sandimmune), digoxin, fexofenadine, paclitaxel, diltiazem, saquinavir, selected chemotherapeutic agents (etoposide, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir), verapamil, oral glucocorticoids, erythromycin, quinidine~* Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period~* Lung cancer history or undergoing chemo- or radiation therapy~* Inflammatory bowel disease~* Child bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sugar chew-Cohort 1 (Type: PLACEBO_COMPARATOR): contains 350 mg of vitamin C and 10 mg niacin
- Quercetin 1-Cohort 1 (Type: ACTIVE_COMPARATOR): Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
- Quercetin 2-Cohort 2 (Type: ACTIVE_COMPARATOR): Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
- Quercetin 3-Cohort 3 (Type: ACTIVE_COMPARATOR): Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
- Sugar chew-Cohort 2 (Type: PLACEBO_COMPARATOR): contains 350 mg of vitamin C and 10 mg niacin
- Sugar Chew-Cohort 3 (Type: PLACEBO_COMPARATOR): contains 350 mg of vitamin C and 10 mg niacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria - all subjects must:~1. Be at least 18 years of age~2. Subjects must have a documented diagnosis of MM and have either refractory or relapsed and refractory after first line treatment disease defined as:~   * Primary refractory~  * Refractory~  * Relapsed and Refractory~3. Subjects must have undergone prior treatment with one treatment line of anti-myeloma therapy. Induction therapy followed by ASCT and consolidation/maintenance will be considered as one line.Have a confirmed diagnosis of MM~4. Have received lenalidomide after one prior treatment for MM and have reached at least a partial response (PR), according to IMWG criteria, including two consolidating cycles. Subjects have experienced a response at least PR after starting treatment with lenalidomide and cortisone cycles.~5. Have personally signed and dated a legally effective written informed consent form prior to admission to the study.~6. Must be willing and able to understand and comply with the study requirements.~7. Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception.~8. Male must agree to practice contraception~Exclusion Criteria:~1. Any of the following laboratory abnormalities:~   * Absolute neutrophil count (ANC) \< 1,000/µL~  * Platelet count \< 75,000/ µL~  * Creatinine Clearance \< 45 mL/min according to Cockcroft-Gault formula~  * Serum SGOT/AST or SGPT/ALT \> 3.0 x upper limit of normal (ULN)~  * Serum total bilirubin \> 2.0 mg/dL~2. ECOG performance status \<4.~3. Individuals who have had a stem-cell transplant as a 2nd line treatment for MM~4. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.~5. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.~6. Pregnant or lactating females.~7. Any other clinically significant medical disease or condition that, in the Investigator´s opinion, may interfere with protocol adherence or a subject´s ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Revlimid (Type: EXPERIMENTAL): None
- Revlimid and dexamethasone (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* First acute or subacute, well-defined neurological event consistent with demyelination (that is, optic neuritis confirmed by an ophthalmologist, spinal cord syndrome, brainstem/cerebellar syndromes)~* Onset of MS symptoms occurring within 90 days of randomization~* A screening MRI scan with 2 or more T2 lesions at least 3 millimeter (mm) in diameter that are characteristic of MS~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease~* Significantly impaired bone marrow function~* Pregnancy or nursing~* Alcohol or drug abuse~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg (Type: PLACEBO_COMPARATOR): Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally.
- Teriflunomide 7 mg/7 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally.
- Teriflunomide 14 mg/14 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PCOS~Exclusion Criteria:~* age \<18 or \>35 years~* BMI \>35 kg/m2~* neoplastic, metabolic, hepatic, renal, and cardiovascular disorders~* Current or previous use of oral contraceptives, glucocorticoids, antiandrogens, ovulation induction agents, antidiabetic and anti-obesity drugs or other hormonal drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Folate (Type: EXPERIMENTAL): Folate plus metformin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo plus metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intervening to Prevent Contextual Errors in Medical Decision Making

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Internal Medicine Residency with continuity of care clinics at either Jesse Brown or Hines VA Medical Centers~Exclusion Criteria:~* All resident physicians who do not meet inclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Seminar and Practicum (Type: EXPERIMENTAL): Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
- No intervention (Type: NO_INTERVENTION): No educational intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent prior to any study-specific activities/procedures~* Ambulatory postmenopausal women.~* Age 55 years or older~* Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck.~Exclusion Criteria:~* Administration of osteoporosis treatments or bone active treatments within specific timeframes~* Vitamin D deficiency~* Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled)~* Contraindications to denosumab therapy (e.g., hypocalcemia)

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab CP2 (Type: ACTIVE_COMPARATOR): Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
- Denosumab CP4 (Type: EXPERIMENTAL): Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Danlou Tablets to Prevent Left Ventricular Remodeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute myocardial infarction~* successfully underwent revascularization~Exclusion Criteria:~* previous myocardial infarction within 30 days~* malignant arrhythmia~* congenital heart disease~* cardiac shock~* documented or suspected history of heart failure or depressed LV ejection fraction \<15%~* planned coronary artery bypass grafting~* a life expectancy of \<1 year~* hepatic impairment~* glomerular filtration rate ≤30 mL/min per 1.73 m2~* autoimmune or connective tissue disease~* chronic substance abuse or psychiatric illness~* unable to complete 3 month clinical follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Danlou Tablets (Type: EXPERIMENTAL): Danlou tablets (4.5 g oral dose taken once daily) for 90 days
- placebo (Type: PLACEBO_COMPARATOR): matching placebo for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in primary school, and attending regularly~* Enrolled in nursery or classes 1-7~* Informed consent from parent or guardian~Exclusion Criteria:~* Enrolled in primary class 8~* Haemoglobin level below 70g/L at baseline~* History of reaction to sulfa drugs (e.g. fansidar, septrin)~* History of severe skin reaction to any drug~Withdrawal criteria:~* Withdrawal of parental consent~* Haemoglobin level falling below 70g/L~* Severe adverse reaction to treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
- 2 (Type: PLACEBO_COMPARATOR): Dual placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* renal artery stenosis~* appropriate size and location of the lesion~* suboptimal angioplasty~Key Exclusion Criteria:~* less than 18 years old~* failure or inability to give informed consent~* simultaneously participating in another drug or device study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): renal artery stenting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete